Menu +

Tag: opinion

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglobulin E (IgE) antibody specifically designed to target and block IgE, a key driver in the inflammatory pathway • Decision based on results from the Phase III POLYP 1 and […]